WUXI BIOLOGICS ADR Aktie

 

DUNDALK, Ireland, June 16, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its Ireland site has been honored with the prestigious 2025 Operational Excellence in Life Sciences Award at......

The HSI ticked up 168 points or 0.7% to close at 24,060. The HSCEI gained 74 points or 0.9% to close at 8,729. The HSTECH hiked 60 points or 1.1% to close at 5,299. Total market turnover for the day was $229.241 billion.Pharma WUXI BIO (02269.HK) stumbled 5.4% to $26.5 as its major shareholder sold 82.94 million shares at a 5% d......

The HSI concluded the midday down 28 points or 0.1% at 23,864. The HSCEI fell 3 points to 8,651. The HSTECH rose 7 points or 0.1% to 5,247. The total half-day turnover for the market amounted to HKD130.885 billion.In the pharma sector, WUXI BIO (02269.HK)'s major shareholder dumped 82.94 million shares at a 5% discount for o......

Hong Kong stocks swung between gains and losses after China reported a mixed bag of economic data from May. The Hang Seng Index rose 0.1 per cent to 23,907.52 as of 10.23am local time. The Hang Seng Tech Index gained 0.4 per cent. On the mainland, the CSI 300 Index climbed 0.1 per cent, and the Shanghai Composite Index added 0.2 per cent. Drug companies led the decline. Wuxi Biologics slumped 6.3 per cent to HK$26.30, Sinopharm Group lost 4 per cent to HK$18.44 and Sino Biopharmaceutical......

Hong Kong stocks opened lower in the morning session. The HSI opened 100 points or 0.4% lower at 23,791. The HSCEI opened 32 points or 0.4% lower at 8,622. The HSTECH opened 32 points or 0.6% lower at 5,207.WUXI BIO (02269.HK) cascaded 3.6% to $27 as its major shareholder sold 82.94 million shares at a 5% discount, cashing in ov......

WUXI BIO (02269.HK) opened 3.57% lower at $27 today (16th), with 84.0969 million shares traded, involving $2.238 billion.Biologics Holdings, controlled by Chairman and Non-executive Director Ge Li, reduced its stake in WUXI BIO. Biologics Holdings entered into a Block Trade Agreement with the Placement Agent Morgan Stanley on Ju......

WUXI BIO (02269.HK) announced that Biologics Holdings, controlled by Chairman and Non-executive Director Ge Li, a major shareholder of the Company, entered into a Block Trade Agreement with the Placement Agent Morgan Stanley on June 14. The Agreement involves the placing of 82.94 million existing shares of the Company, represent......

HONG KONG--(BUSINESS WIRE)--#biotech--Reynold Lemkins Group, an international investment firm focused on value-driven cross-border capital deployment, announced the continued advancement of its strategic focus in late-stage healthcare, AI-powered therapeutics, and Asia-centered biotech commercialization. As part of this strategy, Reynold Lemkins recently participated in the IPO of VISEN Pharmaceuticals on the Hong Kong Stock Exchange (HKEX: 02561). VISEN, a biopharmaceutical company specializing in long-acting growth hormone therapies, attracted strong institutional demand and represents the kind of regulatory-validated, commercially scalable business the firm targets. Reynold Lemkins invested alongside globally recognized healthcare investors including HongShan Capital Group (previously Sequoia China), Sofinnova, Vivo Capital, OrbiMed, and WuXi Biologics (HKEX: 2269), reinforcing its commitment to cross-border innovation and long-term capital alignment. This investment underscores Reynold Lemkins' broad...

The microbial manufacturing site in Chengdu will be equipped with a 15,000L fermenter, enabling the production of 80 to 110 drug substance (DS) batches annually with expansion potential to 60,000L. It will house China's first dual-chamber lyophilization production line and a vial filling......

Anticipation for US-China trade talks in London today (9th) stoked the HSI to open 185 points, or 0.8%, higher at 23,977. Gains manified in early trading, breaking the 24,000 mark, with the index peaking at 24,121, up 328 points, hitting the highest in over two and a half months. It last printed at 24,099, up 307 points or 1.3%,......

~AAStocks Financial NewsWeb Site: www.aastocks.com...

The H shares of pharma inclined today (29th). SINO BIOPHARM (01177.HK) advanced 5.5% to $4.42, while CSPC PHARMA (01093.HK) surged 11.6% after announcing its 1Q results. AKESO (09926.HK) leaped 4%, while WUXI APPTEC (02359.HK) swelled 6.6%. WUXI BIO (02269.HK) shot up 9.8%.The 2025 annual meeting of American Society of Clinical ......

The HSI inched up 150 points or 0.65% to 23,408 at midday. The HSCEI added 57 points or 0.7% to 8,501. The HSTECH climbed 80 points or 1.6% to 5,255. Total half-day turnover of the market amounted to $110.92 billion.Handset parts stocks FIT HON TENG (06088.HK) and SUNNY OPTICAL (02382.HK) jumped up 5.9% and 3.7%, while AAC TECH ......

Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for......

From renewable energy and workforce diversity to local partnerships and sustainable technology, WuXi Biologics' Dundalk site is redefining responsible growth in biomanufacturing. DUNDALK, Ireland, May 13, 2025 /PRNewswire/ -- In the evolving landscape of global biopharmaceutical......

Contributing to United Nations Sustainable Development Goals Enhancing transparency and effectiveness for corporate governance Empowering employees and delivering positive impact to communities Accelerating actions for tackling climate change and promoting environmental stewardship......

Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract......

- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors - Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20% - As the company's largest operational single-use bioreactor to date, the......

SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony. This......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...